K. Inoue

发表

Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer

H. Matsumoto, K. Takai, M. Suganuma, 2021, Scientific Reports.

Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study

H. Iwata, K. Yonemori, N. Masuda, 2022, Breast Cancer.

A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE‐BC

K. Kubota, T. Tamura, J. Tsurutani, 2022, Cancer.

Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

H. Iwata, T. Mukohara, K. Yonemori, 2022, Journal of Clinical Oncology.

Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.

Sung-Bae Kim, H. Iwata, G. Curigliano, 2022, Journal of Clinical Oncology.

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355

H. Iwata, K. Tsugawa, N. Masuda, 2023, Cancer medicine.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Y. Wang, A. Schneeweiss, Ming Yan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.

H. Rugo, H. Iwata, D. Juric, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

K. Inoue, N. Masuda, S. Morita, 2018, Breast Cancer.

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

H. Iwata, T. Mukohara, K. Yonemori, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole

N. Masuda, H. Yasojima, Yasuaki Muramatsu, 2023, Breast cancer.

We're in this together: Patients', caregivers' and health care providers' illness perceptions about non-small-cell lung cancer (NSCLC).

Kenichi Inoue, K. Kubota, Kunihiko Kobayashi, 2015, Lung cancer.